Kymera Therapeutics (KYMR) news
Recent news
Kymathera reports $80M Series B financing
Kymera Therapeutics, Inc. has announced the completion of an $80 million Series B financing round, marking a significant milestone for the biotechnology company. The funding is expected to advance the company’s pipeline of therapeutic candidates and support ongoing research and development…
AInvest Wire · Oct 6, 2026Kymera Therapeutics, Inc.: Citigroup raises target price to $150 from $135
Kymera Therapeutics, Inc. (KYMR) has seen recent analyst activity, with Citigroup raising its price target for the stock to $150 from $135, reflecting increased confidence in the company’s prospects. This adjustment follows a series of analyst actions, including BofA Securities raising its target…
AInvest Wire · Oct 5, 2026Kymera gets upside 90-day catalyst watch at Cit
Kymera Therapeutics (NASDAQ: KYMR) has been placed on Citi’s "upside 90-day catalyst watch," indicating that the firm is monitoring the biopharmaceutical company for potential near-term developments that could positively impact its stock performance. This designation typically reflects expectations…
AInvest Wire · Oct 5, 2026Kymera Therapeutics, Inc.: Stifel raises target price to $152 from $132
Stifel has revised its price target for Kymera Therapeutics, Inc. (KYMR), raising it to $152 from $132, reflecting updated expectations for the company’s financial performance and strategic outlook. The adjustment follows a recent analysis of Kymera’s business operations and market positioning. The…
AInvest Wire · Sep 22, 2026Kymera Therapeutics, Inc.: JP Morgan raises target price to $140 from $121
AInvest Wire · Sep 2, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.